Physostigmine (PHY) is involved in clinical treatments of glaucoma, Alzheimer's disease and has been suggested as an alternative prophylactic treatment against organophosphate poisoning. However, one of the therapeutic uses of physostigmine is limited by short elimination half-life. In this study, P
Polylactide-polyglycolide delivery system for physostigmine
β Scribed by Munir A. Hussain; Joseph A. Mollica
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 274 KB
- Volume
- 82
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
β¦ Synopsis
Cholinergic deficits in Alzheimer's disease have been well documented. Choline acetyltransferase and acetylcholinesterase are consistently reduced in the brain in presenile and senile dementia of the Alzheimer type.'-4 Physostigmine appears to improve memory function in patients with Alzheimer's disease.5.6 Physostigmine is effective parenterally at doses of 5 1 mg,7 and exhibits a very short half-life in human plasma after intravenous (iv) (0.4 h), intramuscular, and subcutaneous (sc) administrations (0.6 h),S and in rat plasma after iv administration (0.6 h1.9 It was suggested that until there is a long-term administration method for cholinomimetics such as physostigmine, it will
π SIMILAR VOLUMES
## Abstract We developed a local drugβrelease system consisting of two biodegradable polymers, poly(sebacic anhydride) (PSA) and polyβD,Lβlactide (PLA), for the treatment of chronic osteomyelitis. PSA and PLA were dissolved and blended at different ratios in tetrahydrofuran. Ofloxacin was loaded wi
## Abstract Antibiotic delivery systems based on biodegradable polymers have found considerable interest for the local therapy of bone infections. In this study polylactide based polymer and composite delivery systems for the release of gentamicin have been fabricated from polyβLβlactides and a pol